𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alemtuzumab promising for residual disease in CLL

Book ID
120857382
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2004
Weight
133 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Alemtuzumab as treatment for residual di
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt